Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Reprogramming fibroblasts to pluripotency using arginine-terminated polyamidoamine nanoparticles based non-viral gene delivery system

Authors Zhu K, Li J, Lai H, Yang C, Guo C, Wang C

Received 8 September 2014

Accepted for publication 25 October 2014

Published 12 December 2014 Volume 2014:9(1) Pages 5837—5847

DOI https://doi.org/10.2147/IJN.S73961

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Thomas J Webster


Kai Zhu,1,2,* Jun Li,1,2,* Hao Lai,1,2 Cheng Yang,1,2 Changfa Guo,1,2 Chunsheng Wang1,2

1Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, 2Shanghai Institute of Cardiovascular Disease, Shanghai, People’s Republic of China

*These authors contributed equally to this article


Abstract: Induced pluripotent stem cells (iPSCs) have attracted keen interest in regenerative medicine. The generation of iPSCs from somatic cells can be achieved by the delivery of defined transcription factor (Oct4, Sox2, Klf4, and c-Myc[OSKM]). However, most instances of iPSC-generation have been achieved by potentially harmful genome-integrating viral vectors. Here we report the generation of iPSCs from mouse embryonic fibroblasts (MEFs) using arginine-terminated generation 4 polyamidoamine (G4Arg) nanoparticles as a nonviral transfection vector for the delivery of a single plasmid construct carrying OSKM (pOSKM). Our results showed that G4Arg nanoparticles delivered pOSKM into MEFs at a significantly higher transfection efficiency than did conventional transfection reagents. After serial transfections of pOSKM-encapsulated G4Arg nanoparticles, we successfully generated iPSCs from MEFs. Our study demonstrates that G4Arg nanoparticles may be a promising candidate for generating of virus-free iPSCs that have great potential for clinical application.

Keywords: mouse embryonic fibroblasts, induced pluripotent stem cells

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]